Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12044296 | 0.90 | GRIN2D (0.55) | BCHEGRIN2DGRIN2CKMT2AMEN1 | |
| SCHEMBL12043913 | 0.84 | GRIN2D (0.70) | BCHEGRIN2DGRIN2CKMT2AMEN1 | |
| SCHEMBL12044324 | 0.80 | RAB9A (0.48) | BCHEGRIN2DGRIN2CKMT2ANPC1 | |
| SCHEMBL12059796 | 0.75 | KEAP1 (0.51) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL12044319 | 0.73 | DHPS (0.60) | GRIN2DGRIN2CKMT2AMEN1NPC1 | |
| SCHEMBL12043935 | 0.72 | GRIN2D (0.79) | GRIN2DGRIN2CKMT2AMEN1POLB | |
| SCHEMBL12043937 | 0.70 | KMT2A (0.70) | GRIN2DGRIN2CKMT2AMEN1POLB | |
| SCHEMBL4467330 | 0.69 | DHODH (0.58) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL25581593 | 0.68 | NR3C1 (0.54) | BCHEKMT2AMEN1 | |
| SCHEMBL11308435 | 0.68 | MAPT (0.49) | GRIN2DGRIN2CKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010088408-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | BCHE 190/4885GRIN2D 8/4885GRIN2C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.